This concept is supported by evidence that GDC-0449 tended to suppress hepatic expression of VEGF/VEGFR1 (data not shown) and increased necrosis in the HCC of GDC-0449-treated mice. This evidence concerns the gene VEGFA and hepatocellular carcinoma.